Illumina, Inc. vs Teladoc Health Inc — how do they compare? Illumina, Inc. trades at $265.87 (market cap $39.95B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: Illumina, Inc. is far larger — about 39.6× Teladoc Health Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Teladoc Health Inc for 39 Days on average.
| ILMN | TDOC | |
|---|---|---|
Market Cap | $39.95B | $1.01B |
Volume | 3,169,503 | 4,668,477 |
Sector | Health | Health |
52-Week High | $293.69 | $9.72 |
52-Week Low | $91.00 | $4.47 |
Typical Hold Time | 83 Days | 39 Days |
Enterprise Value | $41.31B | $1.27B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
TDOC trades at $5.56, down 3.64% today, near multi-year lows with a bearish technical outlook. The stock shows mixed fundamentals with revenue stabilizing around $2.5B but persistent net losses, though improving from 2024's $1B loss to $200M in 2025. Valuation metrics appear attractive with P/S of 0.4 and EV/EBITDA of 5.9, while analyst consensus remains cautiously optimistic with a $8.83 price target.
The outlook remains challenged by ongoing losses and BetterHelp segment weakness, but potential exists if Integrated Care profitability improves and new CFO leadership executes effectively. Key risks include sustained negative cash flow, competitive pressures, and the ongoing SEC investigation highlighted in recent news.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →